Biomatics Capital Partners

Biomatics Capital Partners is a prominent Seattle-based venture capital firm dedicated to investing in transformative healthcare and life sciences companies. Co-founded by Dr. Boris Nikolic, a former science and technology advisor to Bill Gates, and Michael Pellini, a seasoned executive in the diagnostics and life sciences sectors, the firm leverages deep scientific and industry expertise to identify and support groundbreaking innovations. Their investment thesis centers on areas poised for significant disruption and growth, including precision medicine, digital health, biotechnology, and medical devices, aiming to improve patient outcomes and reshape the healthcare landscape.

The firm employs a flexible investment strategy, engaging with companies across various stages, from early-stage (seed and Series A) to growth-stage (Series B and beyond). Biomatics Capital seeks out companies developing novel platforms, therapies, and technologies that address critical unmet medical needs or offer significant advancements in healthcare delivery. Their approach involves not only providing capital but also offering strategic guidance and operational support, leveraging their extensive network and experience to help portfolio companies scale and achieve their milestones.

Biomatics Capital Partners has demonstrated substantial financial capacity through its successful fundraises. The firm closed its inaugural fund, Biomatics Capital Partners I, with $200 million in 2016, establishing its presence as a serious player in the healthcare VC space. Building on this success, they subsequently closed their second fund, Biomatics Capital Partners II, securing $300 million in 2021, bringing their total assets under management to approximately $500 million. This capital base allows them to make significant initial investments and provide follow-on funding to support portfolio companies through multiple growth phases.

While specific initial check sizes can vary depending on the stage and needs of the company, Biomatics Capital typically writes first checks ranging from approximately $5 million for promising early-stage ventures to $20 million for more mature, growth-stage opportunities. Their substantial capital base enables them to lead or co-lead significant funding rounds, positioning them as a key partner for ambitious healthcare and life sciences startups seeking to commercialize their innovations and achieve widespread impact.